|
|
Дата |
|---|
| 20:43 |
| 16.11.2026 |
| 13.11.2026 |
| 12.11.2026 |
| 11.11.2026 |
| 10.11.2026 |
| 09.11.2026 |
| 06.11.2026 |
| 05.11.2026 |
| 04.11.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
0.6033
|
0.6371
|
0.55
|
0.5407
|
0.677
|
0.6205
|
|
|
104 178.87
|
486.00
|
|
0.58
|
0.64
|
0.70
|
0.57
|
0.70
|
0.57
|
|
|
249 750.96
|
995.00
|
|
0.69
|
0.73
|
0.96
|
0.6825
|
0.96
|
0.7001
|
|
|
692 005.41
|
1 961.00
|
|
0.93
|
0.94
|
0.9375
|
0.912
|
0.94
|
0.9259
|
|
|
122 172.36
|
432.00
|
|
0.8808
|
0.94
|
0.94
|
0.90
|
0.94
|
0.9375
|
|
|
98 533.40
|
459.00
|
|
0.8812
|
0.94
|
0.90
|
0.8875
|
0.94
|
0.928
|
|
|
142 756.15
|
377.00
|
|
0.8403
|
0.9195
|
0.84
|
0.81
|
0.9074
|
0.8875
|
|
|
197 606.75
|
473.00
|
|
0.8053
|
0.87
|
0.82
|
0.81
|
0.84
|
0.828
|
|
|
173 678.30
|
520.00
|
|
0.8103
|
0.82
|
0.9055
|
0.8001
|
0.9072
|
0.8078
|
|
|
126 395.30
|
376.00
|
|
0.8605
|
0.8858
|
0.889
|
0.8453
|
0.93
|
0.9038
|
|
|
173 232.10
|
638.00
|
Biofrontera Inc. (Biofrontera) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions. With a focus on the fields of photodynamic therapy (PDT) and topical antibiotics, Biofrontera currently commercializes the FDA-approved flagship drug Ameluz (aminolevulinic acid hydrochloride gel, 10%) in the United States. When used in combination with PDT and Biofrontera’s BF-RhodoLED lamp, Ameluz-PDT is indicated for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions. Biofrontera also commercializes the drug Xepi (ozenoxacin cream, 1%), FDA-approved for the treatment of impetigo.
In collaboration with dermatologists, Biofrontera is fully committed to advancing treatment options and patient care.
Показать все Скрыть| 13.11.2026 |
|
| 13.11.2026 |
|
| 13.08.2026 |
|
| 13.08.2026 |
|
| 14.05.2026 |
|